SCHEMBL29931969

SCHEMBL29931969

O=C(Oc1nc(OCC23CCCN2CCC3)nc2c(F)c(Cl)ncc12)N1C2CCC1CNC2

nearest known ligand 0.45

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30391658 0.85 KRAS (0.64) KRAS
SCHEMBL31282388 0.81 KRAS (0.45) KRAS
SCHEMBL23043219 0.79 KRAS (0.56) KRAS
SCHEMBL23043261 0.79 KRAS (0.56) KRAS
SCHEMBL25379680 0.78 KRAS (0.54) KRAS
SCHEMBL23043121 0.77 KRAS (0.52) KRAS
SCHEMBL29931354 0.77 KRAS (0.52) KRAS
SCHEMBL26981311 0.77 KRAS (0.44) KRAS
SCHEMBL23043428 0.77 KRAS (0.48) KRAS
SCHEMBL25380850 0.76 KRAS (0.51) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS KRAS 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback